• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Q Biomed seeks FDA nod for new manufacturing facility

March 16, 2018 By Sarah Faulkner

Q-BiomedQ Biomed (OTC:QBIO) and Bio-Nucleonics, the company licensing Q Biomed’s strontium chloride injection, have asked the FDA to approval a new manufacturing facility for the drug.

Strontium-89 is a non-opioid injectable designed to relieve pain in patients with metastatic bone disease.

The drug is given in a single injection and takes two weeks to reach its maximum potency within the body, according to CEO Denis Corin. There, it lasts for three to six months without the side effects and addictive qualities associated with opioid pain-killers.

“A lot of these patients are spending the final days of their lives in metastatic disease states really dosed heavily on opiates. It essentially leaves them in like a zombie-like state, because this is such a painful and debilitating condition to be in,” the chief executive told Drug Delivery Business News last year.

The injection was previously approved as a generic with the FDA, but it was shelved when its developer fell ill. Q Biomed picked it up as one of its many pipeline candidates when the company first formed.

Q Biomed is positioning its Sr-89 injection as an affordable and effective alternative to opioids for patients with late-stage cancer. Although the drug is indicated as a pain reliever, Corin believes there is an opportunity to expand the label and market it as a therapeutic.

“The first step is to dust off the ANDA, establish manufacturing facilities, sort of rework it a little bit and get the drug ready for commercial availability, which we’re in the process of doing right now,” he said.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Oncology, Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: qbiomed

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS